Казахстанский фонд iHolding заключил соглашение о покупке акций компании Scilex на сумму около 100 млн долларов

The proposed investment supports the company’s growth initiatives, including healthcare and medical technology projects. It would also fund product development, commercialization, acquisitions, partnerships, and operational expansion. Scilex Signs Binding Term Sheet The company signed a binding term sheet with iHolding, a private investment group headquartered in Almaty, Kazakhstan. Under the term sheet, iHolding would buy newly issued Scilex common shares at an expected purchase price of $15 per share. The investment would represent approximately 6.67 million shares. It plans to use the proceeds for working capital, intellectual property expansion, and other general corporate purposes. Strategic Growth Focus Scilex focuses on acquiring, developing, and commercializing non-opioid pain management products. Its products target acute and chronic pain, neurodegenerative disease, and cardiometabolic disease. The company develops and commercializes non-opioid pain management products for acute and chronic pain. Its portfolio includes ZTlido for neuropathic pain relief and ELYXYB for acute migraine treatment. The proposed investment supports its plan to expand its product line and strengthen its market presence. Scilex Price Action SCLX Price Action: Scilex Holding shares were down 0.13% at $7.80 during premarket trading on Monday, according to Benzinga Pro data. Photo via Shutterstock © 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. To add Benzinga News as your preferred source on Google, click here.